Celularity Inc. Direct Operating Costs
Celularity Inc. (CELU) reported Direct Operating Costs of $27.49 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCosts · last filed 2026-04-30
- Celularity Inc. direct operating costs for the quarter ending 2025-12-31 was -$20.39M.
- Celularity Inc. direct operating costs for the quarter ending 2025-09-30 was $13.90M, a 16.06% decline year-over-year.
- Celularity Inc. direct operating costs for the quarter ending 2025-06-30 was $15.99M, a 18.88% decline year-over-year.
- Celularity Inc. direct operating costs for the quarter ending 2025-03-31 was $17.99M, a 9.47% decline year-over-year.
- Celularity Inc. direct operating costs for fiscal 2025 was $27.49M, a 28.28% decline from fiscal 2024.
- Celularity Inc. direct operating costs for fiscal 2024 was $38.33M, a 4.58% decline from fiscal 2023.
- Celularity Inc. direct operating costs for fiscal 2023 was $40.17M, a 72.15% decline from fiscal 2022.
- Celularity Inc. direct operating costs for fiscal 2022 was $144.20M, a 9.70% decline from fiscal 2021.
| Period end | Direct Operating Costs 3 month | Direct Operating Costs 6 month | Direct Operating Costs 9 month | Direct Operating Costs 12 month | Direct Operating Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$20.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$6.49M derived: sum of 2 quarters · filed 2026-04-30 | $9.50M derived: sum of 3 quarters · filed 2026-04-30 | $27.49M 10-K · filed 2026-04-30 | |
| 2025-09-30 | $13.90M 10-Q · filed 2025-11-14 | $29.89M derived: sum of 2 quarters · filed 2025-11-14 | $47.88M 10-Q · filed 2025-11-14 | $30.06M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-06-30 | $15.99M 10-Q · filed 2025-08-29 | $33.98M 10-Q · filed 2025-08-29 | $16.16M derived: sum of 3 quarters · filed 2026-04-30 | $32.72M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-03-31 | $17.99M 10-Q · filed 2025-08-29 | $173.00K derived: sum of 2 quarters · filed 2026-04-30 | $16.74M derived: sum of 3 quarters · filed 2026-04-30 | $36.45M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$17.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$1.25M derived: sum of 2 quarters · filed 2026-04-30 | $18.45M derived: sum of 3 quarters · filed 2026-04-30 | $38.33M 10-K · filed 2026-04-30 | |
| 2024-09-30 | $16.57M 10-Q · filed 2025-11-14 | $36.27M derived: sum of 2 quarters · filed 2025-11-14 | $56.14M 10-Q · filed 2025-11-14 | $3.74M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $19.71M 10-Q · filed 2025-08-29 | $39.58M 10-Q · filed 2025-08-29 | -$12.82M derived: sum of 3 quarters · filed 2025-08-29 | $3.39M derived: sum of 4 quarters · filed 2025-08-29 | |
| 2024-03-31 | $19.87M 10-Q · filed 2025-08-29 | -$32.53M derived: sum of 2 quarters · filed 2025-08-29 | -$16.32M derived: sum of 3 quarters · filed 2025-08-29 | $5.37M derived: sum of 4 quarters · filed 2025-08-29 | |
| 2023-12-31 | -$52.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$36.19M derived: sum of 2 quarters · filed 2025-05-08 | -$14.50M derived: sum of 3 quarters · filed 2025-05-08 | $40.17M 10-K · filed 2025-05-08 | $81.04M 10-K · filed 2024-07-30 |
| 2023-09-30 | $16.21M 10-Q · filed 2024-12-06 | $37.90M derived: sum of 2 quarters · filed 2024-12-06 | $92.56M 10-Q · filed 2024-12-06 | $122.86M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2023-06-30 | $21.68M 10-Q · filed 2024-11-07 | $76.35M 10-Q · filed 2024-11-07 | $106.65M derived: sum of 3 quarters · filed 2024-11-07 | $142.11M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-03-31 | $54.67M 10-Q · filed 2024-10-16 | $84.97M derived: sum of 2 quarters · filed 2024-10-16 | $120.42M derived: sum of 3 quarters · filed 2024-10-16 | $162.30M derived: sum of 4 quarters · filed 2024-10-16 | |
| 2022-12-31 | $30.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $65.75M derived: sum of 2 quarters · filed 2024-07-30 | $107.63M derived: sum of 3 quarters · filed 2024-07-30 | $144.20M 10-K · filed 2024-07-30 | |
| 2022-09-30 | $35.45M 10-Q · filed 2024-01-03 | $77.33M derived: sum of 2 quarters · filed 2024-01-03 | $113.90M 10-Q · filed 2024-01-03 | $151.79M derived: sum of 4 quarters · filed 2024-01-03 | |
| 2022-06-30 | $41.88M 10-Q · filed 2023-08-14 | $78.44M 10-Q · filed 2023-08-14 | $116.34M derived: sum of 3 quarters · filed 2023-08-14 | $161.75M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $36.57M 10-Q · filed 2023-05-22 | $74.46M derived: sum of 2 quarters · filed 2023-05-22 | $119.87M derived: sum of 3 quarters · filed 2023-05-22 | $171.65M derived: sum of 4 quarters · filed 2023-05-22 | |
| 2021-12-31 | $37.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $83.30M derived: sum of 2 quarters · filed 2023-03-31 | $135.08M derived: sum of 3 quarters · filed 2023-03-31 | $159.69M 10-K · filed 2023-03-31 | $159.69M 10-K · filed 2022-03-31 |
| 2021-09-30 | $45.41M 10-Q · filed 2022-11-10 | $97.18M derived: sum of 2 quarters · filed 2022-11-10 | $121.80M 10-Q · filed 2022-11-10 | $141.70M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $51.77M 10-Q · filed 2022-08-09 | $76.39M 10-Q · filed 2022-08-09 | $96.29M derived: sum of 3 quarters · filed 2022-08-09 | $115.83M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $24.62M 10-Q · filed 2022-05-16 | $44.51M derived: sum of 2 quarters · filed 2022-05-16 | $64.06M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $19.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $39.44M derived: sum of 2 quarters · filed 2022-03-31 | $84.04M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $19.54M 10-Q · filed 2021-11-12 | $64.15M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |